CGRP-REZEPTOR-ANTAGONISTEN
European patent · EP3368526 · In force
Register entry
- Publication number
- EP3368526
- Application number
- EP16808804
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Oct 28, 2016
- Published
- Sep 5, 2018
- Granted
- Dec 25, 2019
- Protection ends at the latest
- Oct 27, 2036
- Next annual fee due
- Oct 31, 2026
- IPC classes
- C07D 401/14 (2006.01)A61P 25/00 (2006.01)A61P 25/06 (2006.01)A61P 29/00 (2006.01)A61K 31/4709 (2006.01)
- Priority
- GB 201519194 30.10.2015
- PCT application
- PCT/IB2016/056519 28.10.2016
- PCT publication
- WO2017/072723 04.05.2017
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Nov 1, 2025
Change
Published in Swissreg on 01.11.2025
- Nov 1, 2024
Change
Published in Swissreg on 01.11.2024
- Oct 30, 2024
Holder’s address changed
- Owner
- Heptares Therapeutics Limited, Granta Park, Great Abington, Cambridge CB21 6DG, United Kingdom → Nxera Pharma UK Limited, Granta Park, Great Abington, Cambridge CB21 6DG, United Kingdom
Published in Swissreg on 30.10.2024
- Jan 26, 2024
Change
Published in Swissreg on 26.01.2024
- Nov 1, 2022
Change
Published in Swissreg on 01.11.2022
- Feb 22, 2020
Agent entered
- Representative
- TR-IP Consulting LLC, Route du Coutset 18, 1485 Nuvilly
Published in Swissreg on 22.02.2020
- Dec 25, 2019
Granted
Published in Swissreg on 25.12.2019
Parties
Inventor
Cambridge CB21 6DG, GB
Cambridge CB21 6DG, GB
Cambridge CB21 6DG, GB
Cambridge CB21 6DG, GB
Cambridge CB21 6DG, GB
Cambridge CB21 6DG, GB
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.